Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing arctigenin and its medicinal use

A technology of arctigenin and composition, which is applied in the field of pharmaceutical composition containing arctigenin and its medical application, and can solve problems such as low curative effect, high recurrence rate, and functional inactivation

Active Publication Date: 2014-10-08
SHANDONG NEWTIME PHARMA
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Standard supportive therapy does not seem to help improve the disease and prolong life. The only measure that can cure MDS is allogeneic hematopoietic stem cell transplantation (ALLOHSCT), but it is not suitable for most elderly patients diagnosed with MDS, and low-dose chemotherapy is effective for moderate Middle- and high-risk patients have low curative effect and high recurrence rate
Due to the abnormal methylation of the genomic DNA of MDS cells, the promoter CpG islands of many important functional genes are highly methylated, and the transcription level is inhibited, resulting in functional inactivation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing arctigenin and its medicinal use
  • Pharmaceutical composition containing arctigenin and its medicinal use
  • Pharmaceutical composition containing arctigenin and its medicinal use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Embodiment 1 injection

[0043] Arctigenin 20g

[0044] Decitabine 10g

[0045] Soybean oil for injection 380g

[0046] Glycerin 120g

[0047] Soy Lecithin 13g

[0048] Add water for injection to 2000ml

[0049] Preparation process: Disperse soybean lecithin and glycerin in 300ml water for injection, then mix arctigenin, decitabine and soybean oil for injection evenly to prepare an oil phase, then add the oil phase to the water phase, Stir while adding, after homogenization, sonicate for 1 hour, then dilute to 2000ml with water for injection, then transfer to a high-pressure homogenizer, emulsify for 30 minutes, fill, and sterilize to obtain.

Embodiment 2

[0050] Embodiment 2 injection

[0051] Arctigenin 30g

[0052] Decitabine 10g

[0053] Soybean oil for injection 360g

[0054] Glycerin 82g

[0055] Soy Lecithin 120g

[0056] Add water for injection to 2000ml

[0057] Preparation process: Disperse soybean lecithin and glycerin in 300ml water for injection, then mix arctigenin, decitabine and soybean oil for injection evenly to prepare an oil phase, then add the oil phase to the water phase, Stir while adding, after homogenization, sonicate for 1 hour, then dilute to 2000ml with water for injection, then transfer to a high-pressure homogenizer, emulsify for 30 minutes, fill, and sterilize to obtain.

Embodiment 3

[0058] Embodiment 3 injection

[0059] Arctigenin 10g

[0060] Decitabine 50g

[0061] Soybean oil for injection 120g

[0062] Glycerin 42g

[0063] Propylene glycol 16g

[0064] Soy Lecithin 5g

[0065] Add water for injection to 800ml

[0066] Preparation process: Disperse soybean lecithin, glycerin and propylene glycol in 120ml of water for injection, then mix arctigenin, decitabine and soybean oil for injection evenly to prepare an oil phase, and then add the oil phase to the water phase , stirring while adding, ultrasonication for 1 hour after homogenization, then dilute to 800ml with water for injection, then transfer to a high-pressure homogenizer, emulsify for 30 minutes, fill, and sterilize to obtain.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicinal composition containing arctigenin and application thereof to preparation of a medicament for treating the myelodysplastic syndrome (MDS). The medicinal composition comprises arctigenin serving as an active ingredient and a DNA (Deoxyribonucleic Acid) methylated transferase inhibitor, wherein the DNA methylated transferase inhibitor comprises decitabine and 5-azacitidine. The medicinal composition disclosed by the invention has a synergistic action for inhibiting the growth of a MDS-RAEB (Myelodysplastic Syndrome-Refractory Anemia with Excess Blast) cell strain SKM-1, and can be used for better treating the MDS.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing arctigenin and its application in preparing medicine for treating cancer, especially the application in preparing medicine for treating myeloid syndrome. Background technique [0002] Malignant tumor is one of the most threatening diseases to human beings, and the research on its treatment is also the most extensive and in-depth. Scientists are tackling the problem in different ways. In recent years, scientists have discovered the cause of epigenetics, especially the discovery that abnormal DNA methylation plays an important role in the occurrence and transformation of tumors. [0003] Myelodysplastic syndrome (Myelodysplastic syndrome, MDS) is a group of heterogeneous hematopoietic stem cell diseases characterized by abnormal blood cell quality and quantity and high risk of acute leukemia. There are 7000-12000 newly diagnosed MDS patients in the United States every year. Although, MDS...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61K31/365A61K31/706A61K31/7068A61P35/00A61P35/02
Inventor 赵志全强红刚
Owner SHANDONG NEWTIME PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com